Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme
Avtorji:ID Koprivnikar Krajnc, Miha (Avtor)
ID Novak, Metka (Avtor)
ID Pestell, Richard G. (Avtor)
ID Lah Turnšek, Tamara (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (914,27 KB)
MD5: DFDF17C3D72C8C62B1B6766F88870112
 
URL URL - Izvorni URL, za dostop obiščite https://doi.org/10.2478/raon-2019-0057
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo NIB - Nacionalni inštitut za biologijo
Povzetek:Background Glioblastoma is the most frequent and aggressive brain tumour in humans with median survival from 12 to 15 months after the diagnosis. This is mostly due to therapy resistant glioblastoma stem cells in addition to intertumour heterogeneity that is due to infiltration of a plethora of host cells. Besides endothelial cells, mesenchymal stem cells and their differentiated progenies, immune cells of various differentiation states, including monocytes, comprise resident, brain tumour microenvironment. There are compelling evidence for CCL5/CCR5 in the invasive and metastatic behaviour of many cancer types. CCR5, a G-protein coupled receptor, known to function as an essential co-receptor for HIV entry, is now known to participate in driving tumour heterogeneity, the formation of cancer stem cells and the promotion of cancer invasion and metastasis. Clinical trials have recently opened targeting CCR5 using a humanized monoclonal antibody (leronlimab) for metastatic triple negative breast cancer (TNBC) or a small molecule inhibitor (maraviroc) for metastatic colon cancer. There are important CCL5 and CCR5 structure and signalling mechanisms in glioblastoma. In addition, the CCL5/CCR5 axis directs infiltration and interactions with monocytes/macrophages and mesenchymal stem cells, comprising glioblastoma stem cell niches. Conclusions CCR5 is highly expressed in glioblastoma and is associated with poor prognosis of patients. CCL5/CCR5 is suggested to be an excellent new target for glioblastoma therapy. The molecular mechanisms, by which chemoattractant and receptor respond within the complex tissue microenvironment to promote cancer stem cells and tumour heterogeneity, should be considered in forthcoming studies.
Ključne besede:cytokines, CCL5-RANTES, glioblastoma, tumour microenvironment, mesenchymal stem cells, signalling
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.12.2019
Leto izida:2019
Št. strani:str. 397-406, II
Številčenje:Vol. 53, no. 4
PID:20.500.12556/DiRROS-20129 Novo okno
UDK:577
ISSN pri članku:1318-2099
DOI:10.2478/raon-2019-0057 Novo okno
COBISS.SI-ID:5234511 Novo okno
Datum objave v DiRROS:06.08.2024
Število ogledov:287
Število prenosov:147
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P1-0245-2019
Naslov:Ekotoksiologija, toksikološka genomika in karcinogeneza

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Cross-Border Cooperation for Slovenia-Italy Interreg TRANS-GLIOMA

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj